AIM: The prevalence of hepatocyte nuclear factor (HNF)-1A and HNF4A mutations, and the clinical implications following the genetic diagnosis of maturity-onset diabetes of the young (MODY) in the Irish population, remain unknown. The aim of this study was to establish the occurrence of HNF1A and HNF4A mutations in subjects classified clinically as MODY to identify novel mutations, and to determine the phenotypic features and response to therapy. METHODS: A total of 36 unrelated index cases with a clinical diagnosis of MODY were analyzed for HNF1A/HNF4A mutations. OGTT was performed to determine the degree of glucose tolerance and insulin secretory response. Also, 38 relatives underwent OGTT and were tested for the relevant known mutations. HNF1A-/HNF4A-MODY subjects were compared with nine HNF1A mutation-negative relatives and 20 type 2 diabetic (T2DM) patients. RESULTS: Seven different HNF1A mutations were identified in 11/36 (30.5%) index cases, two of which were novel (S352fsdelG and F426X), as well as two novel HNF4A mutations (M1? and R290C; 6%). Family screening revealed 20 subjects with HNF1A and seven with HNF4A mutations. Only 51.6% of HNF1A mutation carriers were diagnosed with diabetes by age 25 years; 11 of the mutation carriers were overweight and four were obese. Insulin secretory response to glucose was significantly lower in HNF1A-MODY subjects than in T2DM patients and HNF1A mutation-negative relatives (P=0.01). Therapeutic changes occurred in 48% of mutation carriers following genetic diagnosis. CONCLUSION: There was an HNF1A-MODY pick-up rate of 30.5% and an HNF4A-MODY pick-up rate of 6% in Irish MODY families. Genetically confirmed MODY has significant therapeutic implications.
AIM: The prevalence of hepatocyte nuclear factor (HNF)-1A and HNF4A mutations, and the clinical implications following the genetic diagnosis of maturity-onset diabetes of the young (MODY) in the Irish population, remain unknown. The aim of this study was to establish the occurrence of HNF1A and HNF4A mutations in subjects classified clinically as MODY to identify novel mutations, and to determine the phenotypic features and response to therapy. METHODS: A total of 36 unrelated index cases with a clinical diagnosis of MODY were analyzed for HNF1A/HNF4A mutations. OGTT was performed to determine the degree of glucose tolerance and insulin secretory response. Also, 38 relatives underwent OGTT and were tested for the relevant known mutations. HNF1A-/HNF4A-MODY subjects were compared with nine HNF1A mutation-negative relatives and 20 type 2 diabetic (T2DM) patients. RESULTS: Seven different HNF1A mutations were identified in 11/36 (30.5%) index cases, two of which were novel (S352fsdelG and F426X), as well as two novel HNF4A mutations (M1? and R290C; 6%). Family screening revealed 20 subjects with HNF1A and seven with HNF4A mutations. Only 51.6% of HNF1A mutation carriers were diagnosed with diabetes by age 25 years; 11 of the mutation carriers were overweight and four were obese. Insulin secretory response to glucose was significantly lower in HNF1A-MODY subjects than in T2DM patients and HNF1A mutation-negative relatives (P=0.01). Therapeutic changes occurred in 48% of mutation carriers following genetic diagnosis. CONCLUSION: There was an HNF1A-MODY pick-up rate of 30.5% and an HNF4A-MODY pick-up rate of 6% in Irish MODY families. Genetically confirmed MODY has significant therapeutic implications.
Authors: Shideh Majidi; Alexandra Fouts; Laura Pyle; Christina Chambers; Taylor Armstrong; Zhenyuan Wang; Sat Dev Batish; Georgeanna Klingensmith; Andrea K Steck Journal: Diabetes Technol Ther Date: 2018-02 Impact factor: 6.118
Authors: Qinying Zhao; Li Ding; Ying Yang; Jinhong Sun; Min Wang; Xin Li; Ming Liu Journal: Front Endocrinol (Lausanne) Date: 2022-06-20 Impact factor: 6.055
Authors: C Bonner; K C Nyhan; S Bacon; M P Kyithar; J Schmid; C G Concannon; I M Bray; R L Stallings; J H M Prehn; M M Byrne Journal: Diabetologia Date: 2013-05-15 Impact factor: 10.122
Authors: Avery L McIntosh; Anca D Petrescu; Heather A Hostetler; Ann B Kier; Friedhelm Schroeder Journal: FEBS Lett Date: 2013-10-15 Impact factor: 4.124
Authors: Ma P Kyithar; Caroline Bonner; Siobhan Bacon; Seán M Kilbride; Jasmin Schmid; Rolf Graf; Jochen H M Prehn; Maria M Byrne Journal: J Transl Med Date: 2013-06-26 Impact factor: 5.531
Authors: Christina Chambers; Alexandra Fouts; Fran Dong; Kevin Colclough; Zhenyuan Wang; Sat Dev Batish; Malgorzata Jaremko; Sian Ellard; Andrew T Hattersley; Georgeanna Klingensmith; Andrea K Steck Journal: Pediatr Diabetes Date: 2015-06-08 Impact factor: 4.866